Lobe Sciences Ltd. (LOBEF)
| Market Cap | 6.33M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -3.87M |
| Shares Out | n/a |
| EPS (ttm) | -0.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 104,081 |
| Average Volume | 268,003 |
| Open | 0.0310 |
| Previous Close | 0.0336 |
| Day's Range | 0.0260 - 0.0310 |
| 52-Week Range | 0.0012 - 0.0648 |
| Beta | 2.02 |
| RSI | 43.60 |
| Earnings Date | Jul 24, 2025 |
About Lobe Sciences
Lobe Sciences Ltd., a biopharmaceutical company, engages in the research and development using sub-hallucinatory doses of proprietary psychedelic compounds to improve brain and mental health, and wellness in Canada. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences Ltd. was founded in 2018 and is headquartered in Vancouver, Canada. [Read more]
Financial Performance
In 2024, Lobe Sciences's revenue was 136,205, a decrease of -83.80% compared to the previous year's 840,534. Losses were -4.42 million, -6.09% less than in 2023.
Financial numbers in CAD Financial StatementsNews
Lobe Sciences Announces $341,425 CAD Private Placement for General Corporate Purposes
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / July 29, 2025 / Lobe Sciences Ltd. ("Lobe Sciences" o...
Lobe Sciences Ltd. Engages ArcStone Securities for Strategic Capital Markets Advisory
VANCOUVER, BC / ACCESS Newswire / July 29, 2025 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a biopharmaceutical company focused on developing therapeutics for rare and underserved diseas...
Lobe Sciences Ltd. Announces Debt Settlement
VANCOUVER, BC / ACCESS Newswire / July 16, 2025 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a biopharmaceutical company committed to developing innovative treatments for underserved dise...
Lobe Sciences Announces Validation of European Unitary Patent for DHA-Based Composition for Sickle Cell Disease
European Unitary Patent EP4117446 Validated - Lobe Sciences secures patent protection in 17 EU member states for its DHA and egg yolk-based composition designed to manage Sickle Cell Disease. Covers A...
Lobe Sciences Moves Forward with Development of Conjugated Psilocin(TM) Following April 14 Agreement to Spin Out Compound to Cynaptec Pharmaceuticals
New subsidiary, Cynaptec Pharmaceuticals, established to hold global rights to Conjugated Psilocin™ $6 million investment in Cynaptec Pharmaceuticals secured to advance research and early-stage clinic...
Lobe Sciences Appoints Mr. Yong Yao as Chief Financial Officer to Support Strategic Growth
Lobe Sciences Ltd. has appointed Mr.
Lobe Sciences Ltd. Announces Private Placement to Support Drug Development of Novel Conjugated Psilocin(TM)
Private Placement of US$6 Million to fund additional pre-clinical research, Phase 1 and Phase 2a clinical studies US$20 Million additional option included in Private Placement to fund the Phase 3 clin...
Lobe Sciences Provides Corporate Update
VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / April 4, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a commercial stage biopharmaceutical company focused o...
Lobe Sciences and Alera Pharma Announce Notice of Allowance for Second U.S. Patent for Conjugated Psilocin™
VANCOUVER, British Columbia & STUART, Fla.--(BUSINESS WIRE)--Lobe Sciences, Ltd. ("Lobe Sciences" or the "Company") (CSE: LOBE), (OTCQB: LOBEF) and Alera Pharma, Inc. (“Alera” or “Alera Pharma”), biop...
Lobe Sciences, Ltd. Announces the Appointment of Enclave Capital and Peak Asset Management to Fund Clinical Trials of Conjugated Psilocin™
VANCOUVER, British Columbia--(BUSINESS WIRE)--Lobe Sciences Ltd ("Lobe" or the "Company") (CSE: LOBE), (OTCQB: LOBEF), a biopharmaceutical company focused on developing products to treat diseases with...
Lobe Sciences and Alera Pharma Announce Issuance of U.S. Patent for Conjugated Psilocin™
VANCOUVER, British Columbia & STUART, Fla.--(BUSINESS WIRE)--Lobe Sciences, Ltd. (“Lobe Sciences” or the “Company”) (CSE: LOBE), (OTCQB: LOBEF) and Alera Pharma (“Alera or Alera Pharma”), biopharmaceu...
Lobe Sciences Announces Creation of Wholly Owned Subsidiary, Alera Pharma, Inc.
VANCOUVER, British Columbia--(BUSINESS WIRE)--Lobe Sciences, Ltd ("Lobe Sciences" or the "Company") (CSE: LOBE), (OTCQB: LOBEF), a biopharmaceutical company focused on developing products to treat dis...
Lobe Sciences Announces Appointment of a New Board of Directors and Executive Management Team
VANCOUVER, British Columbia--(BUSINESS WIRE)--Lobe Sciences Ltd ("Lobe Sciences" or the "Company") (CSE: LOBE), (OTCQB: LOBEF), a biopharmaceutical company focused on developing products to treat dise...
Lobe Sciences Announces Update
VANCOUVER, British Columbia--(BUSINESS WIRE)--Company Exploring Alternative Value Creation Opportunities; $500,000 Convertible Note Issued; Balance Sheet Strengthened; AGM Set for 22 July 2024.
Wesley Ramjeet to Join Lobe Sciences' Board of Directors, Bringing Decades of Strategic Financial Expertise
VANCOUVER, British Columbia--(BUSINESS WIRE)--Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to tre...
Lobe Sciences Announces Frederick D. Sancilio Ph.D.
VANCOUVER, British Columbia--(BUSINESS WIRE)--Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to tre...
Former Merck Director and Vanderbilt Vice-Chancellor, Dr. Harry Jacobson, to Join Lobe Sciences Board of Directors
VANCOUVER, British Columbia--(BUSINESS WIRE)--Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to tre...
Lobe Sciences Ltd. and Clearway Global Announce Change of Control and Focus on Creating Value for Shareholders
VANCOUVER, British Columbia--(BUSINESS WIRE)--Lobe Sciences and Clearway Global to Focus on Creating Value for Shareholders, Identify New Board Members, and Strengthen Company Balance Sheet.
Lobe Sciences Provides Company Review of 2023
VANCOUVER, British Columbia--(BUSINESS WIRE)--Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to tre...
Lobe Sciences Provides Update on L-130 Clinical Program
VANCOUVER, British Columbia--(BUSINESS WIRE)--Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to tre...
Lobe Sciences Provides Update on L-130 Oral Psilocin Compound
VANCOUVER, British Columbia--(BUSINESS WIRE)--Lobe Sciences Reports 12 Months Stability for Lead Psilocin Drug Candidate (L-130).
Lobe Sciences, Ltd. Announces The Appointment Of Mathew Lee As CFO
VANCOUVER, British Columbia--(BUSINESS WIRE)--Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical Company committed to discovering and developin...
Lobe Sciences, Ltd. Announces Amendment to the Acquisition of Altemia™ & Company
VANCOUVER, British Columbia--(BUSINESS WIRE)--Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical Company committed to discovering and developin...
Lobe Sciences Announces Additional Details Regarding the Acquisition of Altemia(TM) & Company
Move Affirms Lobe's Position as an Orphan/Rare Disease Drug Development Company and expands portfolio to include 4 Orphan Disease Programs The Company expects to Launch Altemia™, a Medical Food, and G...
Lobe Sciences Initiates Phase 1 Clinical Trial of L-130
VANCOUVER, British Columbia--(BUSINESS WIRE)--First in man trial for Lobe's proprietary stabilized psilocin analogue initiated. All subjects dose with no significant adverse events to date.